Description: The use of Gompertz's law to describe mortality between the ages of 30 and 90 is discussed in this paper. A further use of Gompertz's law, as a tool in comparing mortality tables, is presented for thirty-three modern tables. From Transactions of Society of Actuaries 1981, Vol. 33.

Description: This is a study note that supplements material contained in the book, 'Actuarial Mathematics,' 2nd edition, by N. L. Bowers, Jr., H.U. Gerber, J.C. Hickman, D.A. Jones and C.J. Nesbitt. The topics covered include integer functions, uniform distribution of deaths throughout each year of age, and annuity coefficients.

Description: There is increasing industry interest in applying behavioral science to optimize product design decisions and improve outcomes for both insurers and their customers. With a growing set of options within product designs, predicting consumer behavior continues to get increasingly complex. Join this webcast for an overview of key behavioral economic concepts. Key insights will be shared from two SOA projects that explore how behavioral economic techniques can be used in various parts of the life insurance new business process and inforce management.

Description: This is an internal letter from an actuary to an associate regarding a claims study that established, in the mind of the writer, the adequacy and conclusiveness of a small sample size in certain situations. Actuarial Research Clearing House ARCH 1988, Vol. 3

Description: Results of 2019 survey to their subgroup members.

Description: Actuaries historically modeled new launches in pharmaceuticals by anticipating the expected change to the market basket. This became more complicated with the recent launches of gene and cell therapies as they address rare diseases. Rare conditions have low total member volume to study and some do not currently have a diagnosis code to identify them within claims data. Addressing this modeling challenge has been growing more important in the recent years with the number of therapies launching. What has the health care industry, and more specifically health care, done to enhance modeling and how should this be altered for the future? Additionally, historic modeling has sometimes incorporated a level of direct medical treatment cost offsets where studies have shown lower treatment costs are achievable. Can gene and cell financial modeling include cost offsets as well? And if so, what are suggested precautions or limitations to this effort?

Description: Discusses a method for division of workload in a consulting firm in a way which will minimize cost.

Description: Six methods are presented for calculating the probability of ultimate ruin where the waiting times between claims are independent and identically distributed. Three of the six use Monte Carlo techniques. From Actuarial Research Clearing House 1993, VOL. 1

Description: Abstract for the paper which gives a unified approach to modern credibility models by using the theory of estimating functions.

Description: A review of Section 404 of the Sarbanes-Oxley Act, including a review of the need for life and health insurance actuaries to review and, in most cases, substantially strengthen their internal controls over financial reporting.